Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20. On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study,…